Korean J Intern Med.
2021 Jul;36(4):1001-1013. 10.3904/kjim.2020.549.
Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
- Affiliations
-
- 1Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
- 2Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
- 3Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
- 4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
- 5Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea
- 6Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 7Department of Internal Medicine, College of Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea
- 8Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
- 9Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 10Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
- 11Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 12Department of Internal Medicine, Chung-Ang University H.C.S. Hyundae Hospital, Namyangju, Korea
- KMID: 2517817
- DOI: http://doi.org/10.3904/kjim.2020.549
Abstract
- Background/Aims
Omalizumab is the first biologic known to be effective in patients with severe allergic asthma.
Methods
This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 weeks in Korean patients with severe persistent allergic asthma.
Results
Of the 44 patients, 31.8% were men and the mean age was 49.8 ± 11.8 years. A score improvement of 0.5 points or more in the Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) was noted in 50.0% (22/44) of the patinets. In the improved group, the baseline total immunoglobulin E (IgE) level and the amount of omalizumab used were higher, and the day and night asthma symptoms were more severe, compared to those in the non-improved group. According to the Global Evaluation of Treatment Effectiveness, favorable outcomes were found in 78.6% of patients. The Korean asthma control test (p < 0.005) and forced expiratory volume in 1 second % predicted (FEV1%; p < 0.01) improved significantly in patients who received omalizumab treatment, compared to that at week 0, and the total dose of rescue systemic corticosteroids significantly decreased (p < 0.05). The improved group on KAQLQ showed a significant improvement in FEV1% (p < 0.001).
Conclusions
Omalizumab can be considered a biological treatment for Korean patients with severe allergic asthma. It is recommended to consider omalizumab as add-on therapy in patients with high baseline total IgE levels and severe asthma symptoms.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Real-life Efficacy of Omalizumab After 9 Years of Follow-up
- Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study
- Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
- Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
- Characteristics of depression and anxiety in elderly asthmatics
